Search

Your search keyword '"E. J. Teoh"' showing total 3 results
Start Over Author "E. J. Teoh" Language english
3 results on '"E. J. Teoh"'

1. Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism

Author

G. P. Ralli, R. D. Carter, D. R. McGowan, W.-C. Cheng, D. Liu, E. J. Teoh, N. Patel, F. Gleeson, A. L. Harris, S. R. Lord, F. M. Buffa, and J. D. Fenwick

Subjects
Breast cancer, FDG-PET, RNA sequencing, GSEA, Glycolysis/gluconeogenesis, Immune pathways, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background PET imaging of 18F-fluorodeoxygucose (FDG) is used widely for tumour staging and assessment of treatment response, but the biology associated with FDG uptake is still not fully elucidated. We therefore carried out gene set enrichment analyses (GSEA) of RNA sequencing data to find KEGG pathways associated with FDG uptake in primary breast cancers. Methods Pre-treatment data were analysed from a window-of-opportunity study in which 30 patients underwent static and dynamic FDG-PET and tumour biopsy. Kinetic models were fitted to dynamic images, and GSEA was performed for enrichment scores reflecting Pearson and Spearman coefficients of correlations between gene expression and imaging. Results A total of 38 pathways were associated with kinetic model flux-constants or static measures of FDG uptake, all positively. The associated pathways included glycolysis/gluconeogenesis (‘GLYC-GLUC’) which mediates FDG uptake and was associated with model flux-constants but not with static uptake measures, and 28 pathways related to immune-response or inflammation. More pathways, 32, were associated with the flux-constant K of the simple Patlak model than with any other imaging index. Numbers of pathways categorised as being associated with individual micro-parameters of the kinetic models were substantially fewer than numbers associated with flux-constants, and lay around levels expected by chance. Conclusions In pre-treatment images GLYC-GLUC was associated with FDG kinetic flux-constants including Patlak K, but not with static uptake measures. Immune-related pathways were associated with flux-constants and static uptake. Patlak K was associated with more pathways than were the flux-constants of more complex kinetic models. On the basis of these results Patlak analysis of dynamic FDG-PET scans is advantageous, compared to other kinetic analyses or static imaging, in studies seeking to infer tumour-to-tumour differences in biology from differences in imaging. Trial registration NCT01266486, December 24th 2010.

Published
2022
Full Text
View/download PDF

2. Abstracts of the 33rd International Austrian Winter Symposium

Author

K. Binzel, A. Adelaja, C. L. Wright, D. Scharre, J. Zhang, M. V. Knopp, E. J. Teoh, D. Bottomley, A. Scarsbrook, H. Payne, A. Afaq, J. Bomanji, N. van As, S. Chua, P. Hoskin, A. Chambers, G. J. Cook, V. S. Warbey, A. Chau, P. Ward, M. P. Miller, D. J. Stevens, L. Wilson, F. V. Gleeson, K. Scheidhauer, C. Seidl, M. Autenrieth, F. Bruchertseifer, C. Apostolidis, F. Kurtz, T. Horn, C. Pfob, M. Schwaiger, J. Gschwend, C. D’Alessandria, A. Morgenstern, C. Uprimny, A. Kroiss, C. Decristoforo, E. von Guggenberg, B. Nilica, W. Horninger, I. Virgolini, S. Rasul, N. Poetsch, A. Woehrer, M. Preusser, M. Mitterhauser, W. Wadsak, G. Widhalm, M. Mischkulnig, M. Hacker, T. Traub-Weidinger, E. J. Wuthrick, E. D. Miller, P. Maniawski, Sebastijan Rep, Marko Hocevar, Janja Vaupotic, Urban Zdesar, Katja Zaletel, Luka Lezaic, S. Mairinger, Thomas Filip, M. Sauberer, S. Flunkert, T. Wanek, J. Stanek, N. Okamura, O. Langer, C. Kuntner, M. C. Fornito, R. Balzano, V. Di Martino, S. Cacciaguerra, G. Russo, D. Seifert, M. Kleinova, A. Cepa, J. Ralis, P. Hanc, O. Lebeda, M. Mosa, S. Vandenberghe, E. Mikhaylova, D. Borys, V. Viswanath, M. Stockhoff, N. Efthimiou, P. Caribe, R. Van Holen, J. S. Karp, P. M. Haller, C. Farhan, E. Piackova, B. Jäger, P. Knoll, A. Kiss, B. K. Podesser, J. Wojta, K. Huber, S. Mirzaei, A. Traxl, K. Komposch, Elisabeth Glitzner, M. Sibilia, M. Russello, S. Sorko, H. J. Gallowitsch, S. Kohlfuerst, S. Matschnig, M. Rieser, M. Sorschag, P. Lind, L. Ležaič, S. Rep, J. Žibert, N. Frelih, S. Šuštar, R. P. Baum, T. Langbein, A. Singh, M. Shahinfar, C. Schuchardt, G. F. Volk, H. R. Kulkarni, G. V. Di Martino, W. H. Thomson, M. Kudlacek, M. Karik, H. Rieger, W. Pokieser, K. Glaser, V. Petz, C. Tugendsam, W. Buchinger, B. Schmoll-Hauer, I. P. Schenk, K. Rudolph, M. Krebs, G. Zettinig, V. Zoufal, M. Krohn, T. Filip, J. Pahnke, F. Weitzer, B. Pernthaler, S. Salamon, R. Aigner, P. Koranda, L. Henzlová, M. Kamínek, Mo. Váchalová, P. Bachleda, D. Summer, J. Garousi, M. Oroujeni, B. Mitran, K. G. Andersson, A. Vorobyeva, J.n Löfblom, A. Orlova, V. Tolmachev, P. Kaeopookum, T. Orasch, B. Lechner, M. Petrik, Z. Novy, C. Rangger, and H. Haas

Subjects
Medical physics. Medical radiology. Nuclear medicine, R895-920
Published
2018
Full Text
View/download PDF

3. Selective modification of fluciclovine ((18)F) transport in prostate carcinoma xenografts

Author

J. S. Lee, Funmilayo Tade, Weiping Yu, G. Lu, E. J. Teoh, S. Oka, Baowei Fei, Carlos S. Moreno, David M. Schuster, C. Ormenisan Gherasim, Mark M. Goodman, Dattatraya Patil, H. Okudaira, Adeboye O. Osunkoya, Birdal Bilir, Oladunni Akin-Akintayo, and W. G. Wiles

Subjects
Male, Luminescence, medicine.medical_treatment, Clinical Biochemistry, Carboxylic Acids, Mice, Nude, Biochemistry, Article, 030218 nuclear medicine & medical imaging, Isobutyric acid, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, Mice, 0302 clinical medicine, In vivo, Cell Line, Tumor, Positron Emission Tomography Computed Tomography, medicine, Animals, Humans, Saline, Chemistry, Organic Chemistry, Prostate, Prostatic Neoplasms, Biological Transport, Prostate carcinoma, medicine.disease, In vitro, Partial inhibition, 030220 oncology & carcinogenesis, Cancer research, Heterografts, Cyclobutanes
Abstract

We investigated if previously demonstrated inhibition of fluciclovine ((18)F) in vitro could be replicated in a PC3-Luc xenograft mouse model. Following intratumoral injection of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), alpha-(methylamino)isobutyric acid (MeAIB) or saline, fluciclovine PET tumor-to-background activity was 43.6 (± 5.4)% and 25.3 (± 5.2)% lower in BCH (n = 6) and MeAIB (n = 5) injected PC3 Luc xenografts, respectively, compared to saline-injected controls (n = 2). Partial inhibition of fluciclovine uptake by BCH and MeAIB can be demonstrated in vivo similar to previous in vitro modeling.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results